These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
789 related articles for article (PubMed ID: 17047084)
1. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084 [TBL] [Abstract][Full Text] [Related]
2. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
3. COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. Litchfield LM; Appana SN; Datta S; Klinge CM Mol Cell Endocrinol; 2014 Jan; 382(1):358-367. PubMed ID: 24141032 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749 [TBL] [Abstract][Full Text] [Related]
5. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF). Klinge CM J Steroid Biochem Mol Biol; 1999 Nov; 71(1-2):1-19. PubMed ID: 10619353 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Fan P; Wang J; Santen RJ; Yue W Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173 [TBL] [Abstract][Full Text] [Related]
7. Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Nagasaki S; Suzuki T; Miki Y; Akahira J; Shibata H; Ishida T; Ohuchi N; Sasano H Cancer Sci; 2009 Apr; 100(4):639-45. PubMed ID: 19154418 [TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells. Litchfield LM; Riggs KA; Hockenberry AM; Oliver LD; Barnhart KG; Cai J; Pierce WM; Ivanova MM; Bates PJ; Appana SN; Datta S; Kulesza P; McBryan J; Young LS; Klinge CM PLoS One; 2012; 7(5):e38278. PubMed ID: 22693611 [TBL] [Abstract][Full Text] [Related]
9. The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. Nakshatri H; Mendonca MS; Bhat-Nakshatri P; Patel NM; Goulet RJ; Cornetta K Biochem Biophys Res Commun; 2000 Apr; 270(3):1144-53. PubMed ID: 10772965 [TBL] [Abstract][Full Text] [Related]
10. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance. Pitta CA; Papageorgis P; Charalambous C; Constantinou AI Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064 [TBL] [Abstract][Full Text] [Related]
11. Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. Moré E; Fellner T; Doppelmayr H; Hauser-Kronberger C; Dandachi N; Obrist P; Sandhofer F; Paulweber B J Endocrinol; 2003 Jan; 176(1):83-94. PubMed ID: 12525252 [TBL] [Abstract][Full Text] [Related]
12. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682 [TBL] [Abstract][Full Text] [Related]
13. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines]. Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630 [TBL] [Abstract][Full Text] [Related]
14. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Osipo C; Gajdos C; Cheng D; Jordan VC J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells. Hong W; Chen L; Li J; Yao Z Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620 [TBL] [Abstract][Full Text] [Related]
16. 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Al-Rayyan N; Litchfield LM; Ivanova MM; Radde BN; Cheng A; Elbedewy A; Klinge CM Cancer Lett; 2014 May; 347(1):139-50. PubMed ID: 24513177 [TBL] [Abstract][Full Text] [Related]
17. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412 [TBL] [Abstract][Full Text] [Related]
18. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells. Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen induces the expression of maspin through estrogen receptor-alpha. Liu Z; Shi HY; Nawaz Z; Zhang M Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521 [TBL] [Abstract][Full Text] [Related]
20. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]